BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 30262555)

  • 1. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
    Hoareau-Aveilla C; Quelen C; Congras A; Caillet N; Labourdette D; Dozier C; Brousset P; Lamant L; Meggetto F
    Haematologica; 2019 Feb; 104(2):347-359. PubMed ID: 30262555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
    Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
    J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.
    Desjobert C; Renalier MH; Bergalet J; Dejean E; Joseph N; Kruczynski A; Soulier J; Espinos E; Meggetto F; Cavaillé J; Delsol G; Lamant L
    Blood; 2011 Jun; 117(24):6627-37. PubMed ID: 21471522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK-transformed mature T lymphocytes restore early thymus progenitor features.
    Congras A; Hoareau-Aveilla C; Caillet N; Tosolini M; Villarese P; Cieslak A; Rodriguez L; Asnafi V; Macintyre E; Egger G; Brousset P; Lamant L; Meggetto F
    J Clin Invest; 2020 Dec; 130(12):6395-6408. PubMed ID: 33141118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
    Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
    Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
    Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
    Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
    Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
    Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
    Dejean E; Renalier MH; Foisseau M; Agirre X; Joseph N; de Paiva GR; Al Saati T; Soulier J; Desjobert C; Lamant L; Prósper F; Felsher DW; Cavaillé J; Prats H; Delsol G; Giuriato S; Meggetto F
    Leukemia; 2011 Dec; 25(12):1882-90. PubMed ID: 21778999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
    Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
    Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
    Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells.
    Uchihara Y; Komori R; Tago K; Tamura H; Funakoshi-Tago M
    Biochem Pharmacol; 2019 Dec; 170():113666. PubMed ID: 31654627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
    BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
    Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K
    Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
    Ceccon M; Merlo MEB; Mologni L; Poggio T; Varesio LM; Menotti M; Bombelli S; Rigolio R; Manazza AD; Di Giacomo F; Ambrogio C; Giudici G; Casati C; Mastini C; Compagno M; Turner SD; Gambacorti-Passerini C; Chiarle R; Voena C
    Oncogene; 2016 Jul; 35(29):3854-3865. PubMed ID: 26657151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.